头孢哌酮舒巴坦联合美罗培南治疗老年重症肺炎的临床疗效  

Efficacy of Cefoperazone-sulbactam Combined with Meropenem in the Treatment of Elderly Patients with Severe Pneumonia

作　　者：吴刚[1] 陈腊梅[1] 袁华兵[1] 田思蓝 郭胜红[1] Wu Gang, Chen Lamei, Yuan Huabing, Tian Silan, Guo Shenghong(Department of Pharmacy, the First People ＆ Hospital of Tianmen, Tianmen 431700, Chin)

机构地区：[1]湖北省天门市第一人民医院药剂科

出　　处：《国际老年医学杂志》2018年第2期81-83,共3页International Journal of Geriatrics

摘　　要：目的回顾性研究头孢哌酮舒巴坦联合美罗培南治疗老年重症肺炎的临床疗效。方法选取2014年2月～2015年2月于我院就诊治疗的80例老年重症肺炎患者临床资料，所有患者随机分为对照组（头孢哌酮舒巴坦治疗）和研究组（头孢哌酮舒巴坦联合美罗培南治疗），比较两组患者临床疗效。结果研究组治疗总有效率92．5％，与同期对照组治疗总有效率80％相比较，差异有统计学意义（P〈0．05）；不良反应发生率比较，两组患者分别为15％、10％，组间差异无统计学意义（P〉0．05）；研究组治疗后TNF-α、IL-1、IL-6水平均低于对照组，IL-10水平高于对照组，差异有统计学意义（P〈0．05）。结论头孢哌酮舒巴坦联合美罗培南治疗老年重症肺炎效果优于头孢哌酮舒巴坦单用，可作为临床治疗的优选方案加以推广使用。Objective To investigate the efficacy of cefoperazone - sulbactam combined with meropenem in the treatment of elderly patients with severe pneumonia. Methods A total of 80 elderly patients with severe pneumonia in our hospital from February in 2014 to February in 2015 were recruited. The patients were randomly divided into the control group （ cefoperazone - sulbactam ther- apy） and the experimental group （cefoperazone- sulbaetam combined with meropenem therapy）. The efficacy between two groups were compared. Results The overall efficacy rate was 92. 5% in the experimental group and 80% in the control group. There was a significant difference between two groups （P 〈 0. 05 ）. The incidence of the adverse reactions was 15% in the experimental group and 10% in the control group. There was no significant difference between two groups （ P 〉 0. 05 ）. The levels of TNF - α, IL - 1, IL - 6 in the experimental group were lower than those in the control group, while the level of IL- 10 in the experimental group was higher （ P 〈 0.05 ）. Conclusion Cefoperazone - sulbactam in combination with meropenem is more effective than meropenem alone in the treatment of elderly patients with severe pneumonia.

关 键 词：头孢哌酮舒巴坦 美罗培南 重症肺炎 血清炎性因子 

分 类 号：R563.1[医药卫生—呼吸系统]